Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma
Conditions
Brief summary
This phase II trial is studying how well vorinostat works in treating patients with relapsed or refractory indolent non-Hodgkin's lymphoma. Drugs used in chemotherapy, such as vorinostat, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vorinostat may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Detailed description
PRIMARY OBJECTIVES: I. To evaluate the anti-tumor activity of SAHA (vorinostat) as assessed by the objective response rate, time to progression and survival in subjects with advanced lymphoma. II. To assess the toxicity profile of SAHA in this patient population. III. To perform correlative laboratory investigations to confirm modulation of chromatin acetylation as the biologic target and attempt to gain insight into the downstream molecular mechanisms involved in the induction of apoptosis mediated by SAHA. OUTLINE: Patients receive vorinostat orally (PO) twice daily (BID) on days 1-14. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 1 year and then every 6 months for 2 years.
Interventions
OTHERLaboratory Biomarker Analysis
Correlative studies
DRUGVorinostat
Given PO
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have histologically or cytologically confirmed relapsed/refractory indolent Non-Hodgkin's lymphoma (Included in this category are relapsed/refractory follicular center lymphomas grade I, II, III, relapsed /refractory marginal zone B-cell lymphoma (nodal and extranodal), relapsed/refractory mantle cell lymphoma) * Patients must have measurable disease by computed tomography (CT) scan. positron emission tomography (PET) scan evaluations are desirable but not mandatory, so that patients with negative PET scans but measurable disease by CT are eligible * Patients may have had up to four prior chemotherapeutic regimens; steroids alone and local radiation do not count as regimens (radiotherapy must have been completed at least 14 days prior to starting SAHA); rituxan alone does not count as a regimen, however, Bexxar or Zevalin do; the most recent therapy must have failed to induce a complete response, or there must be disease progression or recurrence after the most recent therapy * Patients may be enrolled who relapse after autologous stem cell transplant if they are at least three months after transplant, and after allogeneic transplant if they are at least six months post transplant; to be eligible after either type of transplant, patients must have achieved platelet counts greater than 100,000/mcL, and white blood cell (WBC) greater than 1,000/mcL at some point after their transplant, and should have no active related infections (i.e. fungal or viral); in the case of allogeneic transplant relapse, there should be no active acute graft versus host disease (GvHD) of any grade, and no chronic graft versus host disease other than mild skin, oral, or ocular GvHD not requiring systemic immunosuppression * Life expectancy of greater than 3 months * Eastern Cooperative Oncology Group (ECOG) performance status #2 (Karnofsky \>= 60%) * Absolute neutrophil count \>= 1,000/mcL * Platelets \>= 100,000/mcL * Total bilirubin within normal institutional limits; patients with elevation of unconjugated bilirubin alone, as in Gilbert's Disease, are eligible * Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT)(serum glutamate pyruvate \[SGPT\]) =\< 2.5 x institutional upper limit of normal * Creatinine up to and including 2 mg/dl * Premenopausal women must have a negative serum pregnancy test prior to entry on this study; the effects of SAHA on the developing human fetus at the recommended therapeutic dose are unknown; women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately * Ability to understand and the willingness to sign a written informed consent document
Exclusion criteria
* Patients who have had chemotherapy within 4 weeks, rituximab within three months (unless there is evidence of progression) or radiotherapy within 2 weeks or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier are excluded; this does not include use of steroids, which may continue until two days prior to enrollment; low dose chlorambucil should be stopped two weeks prior to beginning SAHA; valproic acid should be stopped at least two weeks prior to enrollment; nitrosoureas and mitomycin should be stopped 6 weeks prior to enrollment * Patients may not be receiving any other investigational agents * Patients with known brain metastases are excluded from this clinical trial unless the metastases are controlled after therapy and have not been treated with steroids within the past two months * History of allergic reactions attributed to compounds of similar chemical or biologic composition to SAHA * There must be no plans for the patient to receive concurrent hormonal, biological or radiation therapy * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with SAHA * Human immunodeficiency virus (HIV)-positive patients receiving combination antiretroviral therapy are ineligible * Patients with other active malignancies are ineligible for this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Response Rate | Up to 3 years | Radiological assessment by CT and/or PET scan after every three cycles (every 3 months). Response assessed by the standard Cheson criteria (Cheson et al, J Clin Oncol 17:1244, 1999). Complete Remission (CR) - (a) FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative (b) Variably FDG-avid or PET negative; regression to normal size on CT; Partial Remission (PR) - 50% or greater decrease in SPD of up to 6 largest dominant masses; no increase in size of other nodes (a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site (b) Variably FDG-avid or PET negative; regression on CT. Response Rate = CR + PR. |
| Number of Participants With Adverse Events | Up to 3 years | Grades 3 & 4 adverse events definitely, probably or possibly related to treatment, graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Histone Acetylation by Immunohistochemistry (IHC) | Baseline to up to day 14 | Histone acetylation by IHC will be scored as -, +, ++, or +++, reflecting both the intensity of staining as well as the number of cells stained. Analysis will be descriptive, with the goal of describing baseline distributions and estimating the frequency and degree of changes from baseline. |
| Change in Histone Acetylation by Western Blot (WB) | Baseline to up to day 14 | Histone acetylation by WB will be recorded as the ratio of acetylated histone (measured by photodensitometry) divided by the total histone (H3 or H4), in order to control for the amount of protein loaded. Analysis will be descriptive, with the goal of describing baseline distributions and estimating the frequency and degree of changes from baseline. |
| 2-Year Overall Survival | Until Death from any cause, up to 2 years | Estimated using the product-limit method of Kaplan and Meier. |
| 2-Year Progression Free-Survival | Until death or progression, up to 2 years | Estimated using the product-limit method of Kaplan and Meier. Progression defined as any new lesion or increase by greater than 50% of previously involved sites from nadir. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Treatment (Vorinostat) Patients receive vorinostat PO BID on days 1-14. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Vorinostat: Given PO | 35 |
| Total | 35 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | ineligible | 2 |
Baseline characteristics
| Characteristic | Treatment (Vorinostat) |
|---|---|
| Age, Continuous | 64.5 years |
| Region of Enrollment United States | 35 Participants |
| Sex: Female, Male Female | 12 Participants |
| Sex: Female, Male Male | 23 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 35 / 35 |
| serious Total, serious adverse events | 9 / 35 |
Outcome results
Primary
Number of Participants With Adverse Events
Grades 3 & 4 adverse events definitely, probably or possibly related to treatment, graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0.
Time frame: Up to 3 years
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Treatment (Vorinostat) | Number of Participants With Adverse Events | ANC | 6 Participants |
| Treatment (Vorinostat) | Number of Participants With Adverse Events | Anorexia | 1 Participants |
| Treatment (Vorinostat) | Number of Participants With Adverse Events | Fatigue | 3 Participants |
| Treatment (Vorinostat) | Number of Participants With Adverse Events | Hemoglobin | 4 Participants |
| Treatment (Vorinostat) | Number of Participants With Adverse Events | Hypokalemia | 1 Participants |
| Treatment (Vorinostat) | Number of Participants With Adverse Events | Hyponatremia | 1 Participants |
| Treatment (Vorinostat) | Number of Participants With Adverse Events | Hypophosphatemia | 2 Participants |
| Treatment (Vorinostat) | Number of Participants With Adverse Events | Infection -Skin (cellulitis) | 1 Participants |
| Treatment (Vorinostat) | Number of Participants With Adverse Events | INR | 2 Participants |
| Treatment (Vorinostat) | Number of Participants With Adverse Events | Leukocytes (total WBC) | 4 Participants |
| Treatment (Vorinostat) | Number of Participants With Adverse Events | Lymphopenia | 5 Participants |
| Treatment (Vorinostat) | Number of Participants With Adverse Events | Myalgia | 1 Participants |
| Treatment (Vorinostat) | Number of Participants With Adverse Events | Mucositis/stomatitis | 1 Participants |
| Treatment (Vorinostat) | Number of Participants With Adverse Events | Platelets | 10 Participants |
| Treatment (Vorinostat) | Number of Participants With Adverse Events | Thrombosis/thrombus/embolism | 2 Participants |
Primary
Response Rate
Radiological assessment by CT and/or PET scan after every three cycles (every 3 months). Response assessed by the standard Cheson criteria (Cheson et al, J Clin Oncol 17:1244, 1999). Complete Remission (CR) - (a) FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative (b) Variably FDG-avid or PET negative; regression to normal size on CT; Partial Remission (PR) - 50% or greater decrease in SPD of up to 6 largest dominant masses; no increase in size of other nodes (a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site (b) Variably FDG-avid or PET negative; regression on CT. Response Rate = CR + PR.
Time frame: Up to 3 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Vorinostat) | Response Rate | 29 percentage of participants |
Secondary
2-Year Overall Survival
Estimated using the product-limit method of Kaplan and Meier.
Time frame: Until Death from any cause, up to 2 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Vorinostat) | 2-Year Overall Survival | 77 percentage of participants |
Secondary
2-Year Progression Free-Survival
Estimated using the product-limit method of Kaplan and Meier. Progression defined as any new lesion or increase by greater than 50% of previously involved sites from nadir.
Time frame: Until death or progression, up to 2 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Vorinostat) | 2-Year Progression Free-Survival | 37 percentage of participants |
Secondary
Change in Histone Acetylation by Immunohistochemistry (IHC)
Histone acetylation by IHC will be scored as -, +, ++, or +++, reflecting both the intensity of staining as well as the number of cells stained. Analysis will be descriptive, with the goal of describing baseline distributions and estimating the frequency and degree of changes from baseline.
Time frame: Baseline to up to day 14
Population: Immunohistochemistry data was not collected and is not available for analysis.
Secondary
Change in Histone Acetylation by Western Blot (WB)
Histone acetylation by WB will be recorded as the ratio of acetylated histone (measured by photodensitometry) divided by the total histone (H3 or H4), in order to control for the amount of protein loaded. Analysis will be descriptive, with the goal of describing baseline distributions and estimating the frequency and degree of changes from baseline.
Time frame: Baseline to up to day 14
Population: Western Blot data was not collected and is not available for analysis.